An antioxidant effect by acyclic retinoid suppresses liver tumor in mice.
The mechanisms of prevention of the development of liver cancer by NIK-333, an acyclic retinoid (ACR), were investigated. The transgenic mice expressing the dominant negative form of retinoic acid receptor alpha (RARE mice), that produce reactive oxygen species and lead to development of liver tumor were used. The effect of NIK-333 on hepatocarcinogenesis in RARE mice was studied. The RARE mice were examined after feeding 0.03% and 0.06% NIK-333 diets at 12 months of age. In the mice fed 0.06% NIK-333 diet, tumor incidence was greatly suppressed, compared to that of wild type mice (0/9 versus 5/9, P<0.05), but not in the mice fed 0.03% NIK-333 diet. In addition, expression of cytochrome p450 4a14 and acyl-CoA oxidase was normalized, and the percentages of positive cells for 8-hydroxy-2'-deoxyguanosine, 4-hydroxy-2-nonenal and proliferating cell nuclear antigen were decreased. Furthermore, expression of beta-catenin and cyclin D1 was also depressed. These data suggest that NIK-333 suppressed liver tumor in association with repression of oxidative stress.
Sakabe
Tomohiko
T
Division of Molecular and Genetic Medicine, Department of Genetic Medicine and Regenerative Therapeutics, Graduate School of Medicine, Tottori University, Yonago 683-8504, Japan.
Tsuchiya
Hiroyuki
H
Endo
Michiko
M
Tomita
Akiko
A
Ishii
Kyoko
K
Gonda
Kazue
K
Murai
Rie
R
Takubo
Kazuko
K
Hoshikawa
Yoshiko
Y
Kurimasa
Akihiro
A
Ishibashi
Naoto
N
Yanagida
Shingo
S
Shiota
Goshi
G
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D008113:Liver Neoplasms / Q000517:prevention & control*; D051379:Mice; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
D000975:Antioxidants; D014212:Tretinoin; C034534:3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid